FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2319-2321 December 1, 2005 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Wang, P. S. PubMed Citation

Randomized controlled trials of therapies for the primary and secondary prevention of cardiovascular disease increasingly are powered to study overall mortality. The interventions frequently treat asymptomatic risk factors among high-risk patients and have a diverse spectrum of potential adverse effects. Thus, medications such as clofibrate or encainide that successfully alter surrogate end points but increase the rate of death are of little clinical interest. Many believe that a new preventive therapy for cardiovascular disease should be used sparingly, if at all, until clinical trials establish equivalence or even superiority to existing treatments in terms of mortality from all causes.

When . . . [Full Text of this Article]

Source Information

Dr. Ray is a professor at the Center for Education and Research on Therapeutics, Department of Preventive Medicine, Vanderbilt University School of Medicine, and a research scientist at the Geriatric Research, Education and Clinical Center, Veterans Affairs Medical Center — both in Nashville.

This article has been cited by other articles:

• Ko, G. T.C., So, W.-Y., Tong, P. C., Chan, W.-B., Yang, X., Ma, R. C., Kong, A. P., Ozaki, R., Yeung, C.-Y., Chow, C.-C., Chan, J. C. (2009). Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus. CMAJ 180: 919-926 [Abstract] [Full Text]  
• Phillips McEnany, G. (2007). Psychopharmacologic Strategies and Associated Challenges in the Long-Term Treatment of Schizophrenia. J Am Psychiatr Nurses Assoc 13: S6-S15 [Abstract]  
• Gill, S. S., Bronskill, S. E., Normand, S.-L. T., Anderson, G. M., Sykora, K., Lam, K., Bell, C. M., Lee, P. E., Fischer, H. D., Herrmann, N., Gurwitz, J. H., Rochon, P. A. (2007). Antipsychotic Drug Use and Mortality in Older Adults with Dementia. ANN INTERN MED 146: 775-786 [Abstract] [Full Text]  
• Suissa, S. (2007). Statin Use and Risks for Death and Hospitalization in Chronic Heart Failure. JAMA 297: 1057-1057 [Full Text]  
• Roberts, K., Preston, I., Hill, N. S. (2006). Pulmonary hypertension trials: current end points are flawed, but what are the alternatives?. Chest 130: 934-936 [Full Text]  
• (2005). Mortality Associated with Conventional vs. Atypical Antipsychotic Drugs. JWatch General 2005: 2-2 [Full Text]